Clinical Insight: CFTR Modulators

Volume 8, Issue 6

Clinical Insight: CFTR Modulators

In this issue:

In this issue, Dr. Gregory Sawicki — Associate Professor of Pediatrics at Harvard Medical School and Director of the Cystic Fibrosis Center at Boston Children’s Hospital — discusses how the recent findings about the real-world use of CFTR modulators can impact clinical practice.

Learning objective:

• Summarize the longer-term outcomes of ivacaftor therapy.

• Describe the real-world findings about initiating lumacaftor-ivacaftor therapy.

Author:

Gregory Sawicki, MD, MPH

Director, Cystic Fibrosis Center
Boston Children's Hospital
Associate Professor of Pediatrics
Harvard Medical School
Boston, Massachusetts

Guest Faculty Disclosures

Dr. Sawicki has disclosed that he has served as a principal investigator for Vertex Pharmaceuticals, Novartis AG, and Proteostasis Inc. He has also served or serves on Advisory Boards for Gilead Sciences and Vertex Pharmaceuticals.

Unlabeled/Unapproved Uses

Dr. Sawicki has indicated that there will be no references to the unlabeled/unapproved uses of any drugs or products.

Program Directors:

Peter J. Mogayzel, Jr., MD, PhD

Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University School of Medicine
Baltimore, MD

Noah Lechtzin, MD, MHA

Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Suzanne Sullivan, RN, BSN

Senior Clinical Nurse
The Johns Hopkins University
Baltimore, MD

Guest Faculty Disclosures:

Unlabeled/Unapproved Uses:

Dr. Sawicki has indicated that there will be no references to the unlabeled/unapproved uses of any drugs or products.

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: March 8, 2019
Expiration date: March 7, 2021

Start Issue